
Shares of healthcare solutions company Evolent Health (NYSE:EVH) jumped 15.9% in the afternoon session after Truist upgraded the stock from Hold to Buy and kept its price target unchanged at $6.
CNBC reported that Truist said it sees improved visibility into 2027 following its June 2026 downgrade of the company. According to the report, the firm noted that $150 million or more of EBITDA (earnings before interest, taxes, depreciation and amortization) is increasingly looking achievable for Evolent Health.
Is now the time to buy Evolent Health? Access our full analysis report here, it’s free.
Evolent Health’s shares are extremely volatile and have had 60 moves greater than 5% over the last year. But moves this big are rare even for Evolent Health and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 16 days ago when the stock gained 14.1% on the news that election results confirmed that Democrats reclaimed majorities in the House and Senate, easing regulatory uncertainty around drug pricing policy. As reported by CNBC, Wall Street analysts project that the biopharmaceutical sector's recovery will strengthen in the wake of the congressional election outcome. Investors had feared potential disruptions to healthcare policies, but analysts noted that drug pricing legislation is unlikely to dominate the new legislative agenda. Prior statutory frameworks already established expanding annual Medicare price negotiations, meaning existing government policies will remain intact without unexpected new restrictions.
Furthermore, broader equity markets and index futures rebounded as investors interpreted the shifting balance of power in Washington as a stabilizing dynamic. The presence of congressional checks and balances is widely viewed by market strategists as a moderating force on executive policy decisions, creating a predictable regulatory climate that supports ongoing investments across pharmaceutical and biotechnology developers.
Evolent Health is flat since the beginning of the year, and at $3.91 per share, it is trading 36.9% below its 52-week high of $6.19 from July 2026. Investors who bought $1,000 worth of Evolent Health’s shares 5 years ago would now be looking at only $136.83.
ALSO WORTH WATCHING: Nvidia’s Quiet Partner. Nvidia’s chips cost a hundred grand. The connectors that make them work cost even more. One company makes them all.
Every AI server needs specialized infrastructure the chip companies don’t make. High-speed cables. Power connectors. Thermal sensors. This 90-year-old company built a monopoly on it. The AI boom just started. This stock is still flying under the radar. Claim The Stock Ticker Here for FREE.